annb0t
Top 20
MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).1 (PRNewsfoto/Telix Pharmaceuticals Limited)
The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud Univer...
>>> Read more: Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud Univer...
>>> Read more: Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
